Drug intelligence / Profile preview

AMGT-0220

Development stage: Preclinical
Lead developer: Amalgent Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AMGT-0220 is an investigational oral fixed-dose combination of **morphine** and **pramipexole** being developed by Amalgent Therapeutics for acute and severe pain. Morphine provides analgesia primarily through mu-type opioid receptor agonism, while pramipexole activates dopamine D2/D3 autoreceptors. The combination is designed to maintain analgesia at a reduced morphine dose while reducing opioid reward-related signaling, tolerance, and abuse liability. The technology originated at East Carolina University and is being commercialized by Amalgent Therapeutics. ([reporter.nih.gov](https://reporter.nih.gov/project-details/10760487))

Other names: morphine + pramipexole

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on AMGT-0220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMGT-0220.

Explore the full profile